Published • loading... • Updated
Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
Studies in 1,549 patients found the Canopy Remote Therapeutic Monitoring platform cut hospitalizations 28% and saved about $3.1 million per 1,000 patients.
- On Thursday, May 21, 2026, Canopy announced two studies on its remote therapeutic monitoring platform were selected for presentation at the 2026 American Society of Clinical Oncology Annual Meeting.
- The Canopy RTM Platform enables practices to identify and prioritize patients using AI-native tools, aiming to reduce hospitalizations and increase time on treatment for oncology patients.
- A study of 1,549 patients with metastatic solid tumors showed a 28% reduction in hospitalizations and $3.1 million in estimated annual savings, said James Essell, MD, Advisor at Cincinnati Cancer Advisors.
- Tracking 1,598 patients receiving immune-checkpoint inhibitor therapy, researchers observed a 51% lower risk of hospitalization and $12.6 million in estimated annual cost savings, reported Benjamin Derman, MD, Assistant Professor of Medicine at the University of Chicago Medicine.
- The Canopy RTM platform improved detection of potential immune-related symptoms including rash and difficulty breathing, helping patients achieve 79% longer median time to treatment discontinuation.
Insights by Ground AI
17 Articles
17 Articles
Bennington Banner+16 Reposted by 16 other sources
Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
New data demonstrate the potential of the Canopy Remote Therapeutic Monitoring (RTM) Platform to improve patient care by reducing hospitalizations and increasing time on treatment.
Coverage Details
Total News Sources17
Leaning Left4Leaning Right1Center7Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 33%
C 59%
Factuality
To view factuality data please Upgrade to Premium
